Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, Martin Lopez AA, Iraola-Truchuelo J, Delgado J, Perez A, Guerreiro M, Caballero AC, Martinez-Cibrian N, Luzardo Henriquez H, Sanchez Pina JM, Sancho JM, Ghesquieres H, Mussetti A, Lopez Corral L, Hernani R, Reguera JL, Sureda A, Bosch F, Martin Garcia-Sancho A, Kwon M, Subklewe M, Kuhnl A, Bachy E, Barba P, Villacampa G, Abrisqueta P. Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.. Journal of Hematology & Oncology. 2024; 17(1)DOI:10.1186/s13045-024-01608-8. PMID:39468591. IF:(Q/D).

Bailén, R, Iacoboni, G, Delgado, J, López-Corral, L, Hernani-Morales, R, Ortiz-Maldonado, V, Guerreiro, M, Caballero, AC, Guerra-Domínguez, ML, Sánchez-Pina, JM, Peña, M, Torrent, A, Pérez-Martínez, A, Bastos-Oreiro, M, Reguera-Ortega, JL, Martín, A, Hernandez-Boluda, JC, Martínez-Cibrián, N, Sanz, J, Briones, J, Henriquez, HL, Calbacho, M, Mussetti, A, Sancho, JM, Barba, P, Kwon, M. Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO. Transplantation And Cellular Therapy. 2024; 30(10)DOI:10.1016/j.jtct.2024.06.022. PMID:39069076. IF:4.400(Q1/1D).

Spyridonidis, A, Labopin, M, Savani, B, Kulagin, A, Blaise, D, Versluis, J, Sica, S, Raiola, AM, Vydra, J, Choi, G, Rovira, M, Kwon, M, Sanz, J, It la-Remes, M, Borne, PV, Martino, R, Koc, Y, Brissot, E, Nagler, A, Mohty, M, Ciceri, F. THE IMPACT OF INDIVIDUAL COMORBIDITIES ON NRM RISK FOLLOWING PTCY BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN ALWP EBMT STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Serrano, JD, Corral, LL, Valc rcel, D, Sierra, J, Ferra-Coll, C, Velazquez, TC, Dom nguez, FM, Le n, RJ, Ortega, JLR, Go i, CB, L pez, EP, Mart nez, AC, Cadenas, IG, Sim n, JAP. DELAYED ADMINISTRATION OF IXAZOMIB AS PROPHYLAXIS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Gagelmann, N, De Witte, M, Peczynski, C, Boreland, W, Broers, A, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Byrne, J, Bethge, W, Maertens, J, St lzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kr ger, N, Corradini, P, Finazzi, MC, Corral, L, Villar, S, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

G mez, VE, Corral, LL, Mahillo, BA, Mellado, PA, Dom nguez, FMM, G mez, MA, Cant , PA, G mez, JM, Ochando, MT, Borrego, AB, Pinedo, LG, Ripa, MTZ, Vicent, MG, Vallejos, AB, Izquierdo, I, Cadenas, IG, Velao, SR, Musseti, A, Giro, EC, Moraleda, PP, Pascual, GO, Sierra, PAG, Garc a, L, Guti rrez, VG, P rez-Sim n, JA. RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Salas, MQ, Solano, MT, Baile-Gonz lez, M, Acera-G mez, M, Fox, L, del Mar P rez-Artigas, M, Santamar a, A, Quintela-Gonz lez, MDC, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Gonz lez, SR, Mussetti, A, Lavilla, E, L pez-Marin, J, Cedillo, A, Bento, L, Sureda, A. FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Fern ndez-Barge, T, Dom nguez-Garcia, JJ, Escamilla, MS, Caballer, JS, Chorao, P, Boluda, JCH, Velao, SR, Cadenas, IG, Bufarull, RM, Estefania, RC, Alexandre, IF, Pe a, AG, Garc a, AT, Ruiz, RG, Luis, SF, San Miguel, EMO, Ara jo, MC, Pell n, SGD, Rodr guez, MAB. OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).